EXPERIENCE OF USE OF NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY WITH DOXORUBICIN AND CISPLATIN IN COMBINED TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER: PROSPECTIVE SINGLE-CENTER NON-RANDOMIZED CONTROLLED STUDY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective: to evaluate the results of the use of dose-intensive neoadjuvant chemotherapy (NACT) with doxorubicin and cisplatin in patients with locally advanced cervical cancer stage IB2-IIB. Methods. In the patients participating in the study, the efficacy and toxi-city of 3 cycles of intravenous dose-intensive NACT according to the AP scheme (cisplatin 75 mg/m2, doxorubicin 35 mg/m2) and subsequent radical surgical intervention in 62 (89%) cases were evaluated. Results. The study involved 70 patients with locally advanced cervical cancer at the age of 27-68 years (mean age, 45 years). Against the background of the treatment, an objective response was received from 58 (83%) patients. Progression of the disease was detected in 6 (8.6%) cases; relapse of the disease was diagnosed in 2 (2.8%) patients. Neoadjuvant therapy allowed to perform radical surgical intervention in 61 (87.1%) patients. The tumor pathomorphological response of various degrees was obtained in 58 (82.8%) cases; complete clinical regression of the tumor was confirmed by a complete pathomorphological response in 5 (7.14%) of these cases. The dose-intensive regimen of chemotherapy did not lead to significant complications at the pharmacological and surgical stages of treatment. Conclusion. Analysis of the study results has showed that dose-intensive NACT is an effective method and can be considered as an alternative to standard treatment of locally advanced cervical cancer.

全文:

受限制的访问

作者简介

O. Smirnova

N.N. Petrov National Medical Research Center of Oncology

Email: ssmirnova.oa@gmail.com

N. Bondarev

N.N. Petrov National Medical Research Center of Oncology

A. Petrova

N.N. Petrov National Medical Research Center of Oncology

K. Guseinov

N.N. Petrov National Medical Research Center of Oncology

N. Mikaya

N.N. Petrov National Medical Research Center of Oncology

A. Artemyeva

N.N. Petrov National Medical Research Center of Oncology

T. Gorodnova

N.N. Petrov National Medical Research Center of Oncology

E. Nekrasova

N.N. Petrov National Medical Research Center of Oncology

O. Lavrynovych

N.N. Petrov National Medical Research Center of Oncology

V. Bashlyk

N.N. Petrov National Medical Research Center of Oncology

A. Nyuganen

N.N. Petrov National Medical Research Center of Oncology

A. Abramova

N.N. Petrov National Medical Research Center of Oncology

A. Sidoruk

N.N. Petrov National Medical Research Center of Oncology

E. Ulrikh

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

T. Semiglazova

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

A. Urmancheeva

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

I. Berlev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

参考

  1. Torre L.A., Bray F., Siegel R.L., et al. Global Cancer Statistics, 2012. CA Cancer J. Clin. 2015; 65:87-108.
  2. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2005;23(21):4626-33.
  3. Ульрих Е.А., Тамбиева З.А., Урманчеева А.Ф., Моисеенко В.М. Качество жизни больных раком шейки матки I, II стадий после радикальных методов лечения. Вопросы онкологии. 2007;53(5):717-21.
  4. Rydzewska L., Tierney J., Vale C.L., Symonds P.R. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database System. Rev. 2012;12:CD007406. doi: 10.1002/14651858.CD007406.pub3.
  5. Dueck A.C., Mendoza T., Mitchell S., et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE) JAMA. Oncol. 2015;1(8):1051-59. doi: 10.1001/jamaoncol.2015.2639.
  6. Benedetti-Panici P., Scambia G., Greggi S., et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study. Obstet. Gynecol. 1988(Pt. 1):344-48.
  7. Benedetti-Panici P., Greggi S., Colombo A., et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J. Clin. Oncol. 2002;20(1):179-88.
  8. Choi Y.S., Sin J.I., Kim J.H., et al. Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer. J. Korean. Med. Sci. 2006;21:683-89.
  9. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur. J. Cancer. 2003;39(17):2470-86.
  10. U.S. National Library of Medicine. ClinicalTrials.gov. [электронный ресурс] Режим доступа: https:// clinicaltrials.gov/ct2/home.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2018
##common.cookie##